GlassScriptPhysician profile
Laura K Bianchi
NPI 1932231115
$2,133.02
in general payments reported to CMS, 2019-2025
18 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $14.82 · 2024: $1,057 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,995 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,994.51 |
| Education | $138.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $298.68 | 2024-2025 | Entyvio, Vpriv |
| Janssen Biotech, INC. | $256.51 | 2025 | Tremfya |
| Abbvie INC. | $240.82 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.72 | 2024-2025 | Xifaxan |
| Ardelyx, INC. | $148.84 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $148.58 | 2024-2025 | Resmetirom, Rezdiffra |
| Abbott Laboratories | $147.40 | 2024 | 2nd Gen Centrimag Primary Console |
| Celltrion USA INC. | $142.83 | 2024-2025 | Vegzelma, Zymfentra |
| Qol Medical, LLC | $128.15 | 2024-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $113.29 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $107.65 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $81.27 | 2024-2025 | |
| Mauna Kea Technologies, INC. | $37.11 | 2024 | |
| Braintree Laboratories, INC. | $32.87 | 2024 | Sutab, Suflave |
| Lilly USA, LLC | $26.09 | 2025 | Omvoh |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $21.60 | 2025 | Qsymia |
| Olympus America INC. | $16.37 | 2025 | Evis Exera III Colonovideoscope |
| Echosens North America, INC. | $15.24 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Bianchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.